Evidence map›Paper›PMID 39606335›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Integrative multi-omics profiling of colorectal cancer from a Hispanic/Latino cohort of patients.

B Waldrup, F Carranza, Y Jin, Y Amzaleg, M Postel, D W Craig, J D Carpten, B Salhia, C N Ricker, J O Culver and 5 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

B WaldrupCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0009-0009-7620-1451
F CarranzaCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0003-1789-4197
Y JinCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0002-6124-9681
Y AmzalegCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0002-8576-9702
M PostelUniversity of Southern California, Keck School of Medicine of USC, Department of Translational Genomics, Los Angeles, CA.ORCID 0000-0002-9438-1283
D W CraigCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0001-9427-4202
J D CarptenCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0002-6862-2821
B SalhiaUniversity of Southern California, Keck School of Medicine of USC, Department of Translational Genomics, Los Angeles, CA.ORCID 0000-0003-3843-3621
C N RickerUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.
J O CulverUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0000-0001-8658-3507
C E ChavezUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.
M C SternUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0000-0001-9777-4683
L Baezconde-GarbanatiUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0000-0003-2713-9435
H J LenzUniversity of Southern California, USC Norris Comprehensive Cancer Center, Los Angeles, CA.ORCID 0000-0003-2178-9568
E I Velazquez-VillarrealCity of Hope, Beckman Research Institute, Department of Integrative Translational Sciences, Duarte, CA.ORCID 0000-0002-3603-6414

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization StudiesU2CCA252971 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOHN D. CARPTEN, HEINZ JOSEF LENZ · 2021 to 2026
$19.3M
NCI NIH HHS P30 CA033572NCI NIH HHS U2C CA252971
6 · The paper itself

Abstract

Colorectal cancer contributes to cancer-related deaths and health disparities in the Hispanic and Latino community. To probe both the biological and genetic bases of the disparities, we characterized features of colorectal cancer in terms of somatic alterations and genetic similarity. Specifically, we conducted a comprehensive genome-scale analysis of 67 Hispanic and Latino samples. We performed DNA exome sequencing for somatic mutations, somatic copy number alterations, and genetic similarity. We also performed RNA sequencing for differential gene expression, cellular pathways, and gene fusions. We analyzed all samples for 22 important CRC gene mutations, 8 gene amplifications, and 25 CRC gene fusions. Then, we compared our data from the Hispanic and Latino samples to publicly available, Non-Hispanic White (NHW) cohorts. According to our analyses, twenty-four percent of colorectal carcinomas were hypermutated when patients were of Peruvians-from-Lima-like (1KG-PEL-like) genetic similarity population from the 1000 genome project. Moreover, most of these cases occurred in patients who were less than fiay years old age at diagnosis. Excluding hypermutated tumors, approximately 55% of colon cancers and 58% of rectum cancers exhibited two similar features: 1) the paderns of genomic alterations; 2) percentage of 1KG-PEL-like. We analyzed all samples -- which had a median 1KG-PEL-like proportion of 55% -- for 22 important CRC gene mutations, 8 gene amplifications, and 25 CRC gene fusions. One notable example of a frequently observed gene mutation was SMAD4. Samples with SMAD4 alterations, which are known to support tumor growth and progression, had the highest 1KG-PEL-like proportion (63%). According to our results from risk association analyses and differential gene expression, SMAD4 alterations were significant when we compared Hispanic and Latino samples to NHW cohorts. Of the 8 drug-targetable amplifications, PIK3CA and PI3K exhibited an average 1KG-PEL-like of over 55%. Of the 25 relevant CRC gene fusions, targetable genes included ALK, FGFR1, RAF1, and PTPRK; PTPRK was observed in a sample with the highest 1KG-PEL-like proportion (95%). Using Integrative analysis, we also detected recurrent alterations in the WNT, TGFB, TP53, IGF2/PI3K, and RTK/RAS pathways. Importantly, these alterations mostly occurred in young patients with high 1KG-PEL-like. These findings highlight the potential for tailoring precision medicine therapeutics to an underrepresented population. Our study advances the molecular profiling of CRC in Hispanics and Latinos. In toto, genetic similarity appears to be an important component in understanding colorectal carcinogenesis and has the potential to advance cancer health disparities research.

Identifiers

PMID39606335
PMCPMC11601710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.